Physician profile
Jing Zhou
NPI 1497085278
$256.57
in general payments reported to CMS, 2019-2025
12 companies · $55.38 in 2025
The $55.38 reported for 2025 was more than what a typical Anatomic Pathology & Clinical Pathology provider received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.15 · 2020: $69.32 · 2023: $55.36 · 2024: $14.36 · 2025: $55.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $125.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $36.49 | 2023 | Indigo System |
| Abbvie INC. | $31.70 | 2024-2025 | |
| Seagen INC. | $28.56 | 2019-2020 | |
| Incyte Corporation | $22.53 | 2025 | Zynyz, Monjuvi |
| Pharmacyclics LLC, An Abbvie Company | $21.84 | 2020 | |
| Beckman Coulter, INC. | $18.87 | 2023 | Dxc Au |
| Angiodynamics, INC. | $17.98 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $17.26 | 2019 | |
| Foundation Medicine, INC. | $15.73 | 2020 | |
| Clovis Oncology, INC. | $15.55 | 2019 | |
| Daiichi Sankyo INC. | $15.51 | 2025 | Enhertu |
| Celgene Corporation | $14.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jing Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.